NTVH - 2021, nummer Hematologie Actueel, december 2021
dr. C. Geest
Uit de onlangs gepubliceerde resultaten van de ASCEMBL-studie onder patiënten met chronische myeloïde leukemie in de chronische fase blijkt dat behandeling met de STAMP-remmer asciminib bijna twee keer zo effectief is als de traditionele tyrosinekinaseremmer bosutinib, ook na drie of meer eerdere behandellijnen met andere tyrosinekinaseremmers.
Lees verderTo provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
